Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GSK
Biotech
GSK axes vaccine from $2.1B deal, switches to preclinical heir
GSK has axed a pneumococcal 24-valent vaccine for adults from its $2.1 billion Affinivax takeover in favor of a preclinical 30-plus valent shot.
Nick Paul Taylor
Oct 30, 2024 7:06am
GSK aims to extend lupus dominance via $300M T-cell engager deal
Oct 29, 2024 8:00am
GSK and Cambridge scientists join forces in $65M immune R&D deal
Oct 22, 2024 3:30pm
GSK and Boston scientists team up to tackle lung diseases
Oct 18, 2024 11:26am
Wave hails human RNA editing first for GSK-partnered prospect
Oct 16, 2024 10:22am
GSK blockbuster hope depemokimab shrinks polyps in ph. 3 trials
Oct 14, 2024 4:51am
